Ellagic Acid May Slow Growth of Some Cancer Tumors

Ellagic acid is a, ‘phytochemical,’ or plant chemical that is found in strawberries, cranberries, raspberries, pecans, walnuts, pomegranates and other plant foods. Research in laboratory animals and cell cultures has discovered that ellagic acid might slow the rate of growth of some tumors caused by certain carcinogens. Even though this is promising, there remains no reliable evidence at this time from human clinical studies showing that ellagic acid has the ability to either prevent or treat forms of cancer. Additional research is required in order to determine what benefits it may have.
Source: Disabled World - Category: Disability Tags: Nutrition Source Type: news

Related Links:

Authors: Garcia MB, Ness KK, Schadler KL Abstract Exercise has the potential to positively affect patients with osteosarcoma by improvement of function, mitigation of disability, and maintenance of independence and quality of life. Exercise may also directly impact cancer treatment efficacy. This chapter examines the feasibility and use of exercise or physical activity as therapy in the treatment of osteosarcoma and its survivors. It additionally presents the benefits of physical activity as treatment and rehabilitation both preoperatively (prehabilitation) and postoperatively. This chapter will also discuss barrie...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
ConclusionsEndocrine dysfunction among CCSs has a high prevalence in the transition age and increase with time. Many endocrine disorders, including GHD, are often not diagnosed or under-diagnosed, probably due to the lack of specialized centers for the long-term follow-up. Therefore, it is crucial that transition specialized clinics should be increased in terms of number and specific skills in order to manage endocrine disorders in adolescence, a delicate and complex period of life. A multidisciplinary approach, also including psychological counseling, is essential in the follow-up and management of these patients in order...
Source: Pituitary - Category: Endocrinology Source Type: research
We report herein that individuals with disabilities have a relatively low diagnosis rate of acute myeloid leukemia (AML), undergo less active treatment, and have significantly lower survival rates than those without a disability. AbstractWe analyzed the patterns of diagnosis, treatment, and prognoses of acute myeloid leukemia (AML) patients with and without disabilities. The data were collected from the National Disability Database, the Korean Central Cancer Registry, and the Korean National Health Insurance claim database. We built a cohort of 2  776 450 people with disabilities and a nondisabled cohort of 8&nbs...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
Conclusion: The burden of disease (BD) increased by 1.6% from 1990 to 2015. The main causes were migraine, CVD, and NE. ADD and NSC doubled the DALY in this period. These diseases represent a significant cause of disability attributable to the increase in the life expectancy of our population among other factors. Priority actions should be taken to prevent and treat these causes.RESUMEN Introducci ón: Los indicadores de carga de la enfermedad evalúan el impacto que producen las enfermedades en una población. Integran la mortalidad y discapacidad en un solo indicador. Esto permite fijar prioridades para...
Source: Arquivos de Neuro-Psiquiatria - Category: Neurology Source Type: research
ConclusionsScreening for ADL impairments is needed for older cancer survivors as Katz ADL disability differs by cancer type, stage, and age with greater impairment with advanced age and stage.Implications for cancer survivorsInterventions to address ADL limitations should be considered for older cancer survivors.
Source: Journal of Cancer Survivorship - Category: Cancer & Oncology Source Type: research
AbstractPurpose of ReviewTo review the clinical evidence of the effect of aspirin as primary prevention for patients with diabetes mellitus and in healthy elderly.Recent FindingsTwo trials were performed to study these two patient populations: ASCEND showed that the use of low-dose aspirin in persons with diabetes, who did not have prior cardiovascular disease, led to a lower risk of cardiovascular events than placebo (8.5% vs 9.6%, rate ratio 0.88, 95% CI 0.79 –0.97;p = 0.01). However, it showed a similar magnitude of increased risk of major bleeding among the aspirin group compared with placebo (4.1% ...
Source: Current Cardiology Reports - Category: Cardiology Source Type: research
Head and neck cancer is increasing globally owing to rising rates of tobacco use and human papillomavirus infection. Today, cancer is the leading cause of death and disabilities in developed countries and the second leading cause of death in countries with developing economies. Understanding the global landscape of head and neck cancer will empower oral and maxillofacial surgeons to play a critical role among patients and societal education regarding the importance of addressing modifiable risk factors and continuing to play an important role in the diagnosis and management of head and neck cancer.
Source: Oral and Maxillofacial Surgery Clinics - Category: ENT & OMF Authors: Source Type: research
Conditions:   Fatigue;   Leukemia;   Lymphoma;   Physical Disability Interventions:   Other: Standard protocol Leukemia;   Other: Periodic Resistance Training Program Leukemia;   Other: Standard protocol Lymphoma;   Other: Periodic Resistance Training Program Lymphoma Sponsor:   Federal University of Health Science of Porto Alegre Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Putting physical disability on view in the highly competitive arena of classical music takes grit; playing with invisible disease seemed even more terrifying to me.
Source: NYT Health - Category: Consumer Health News Authors: Tags: Music Classical Music Prostate Cancer Coronavirus (2019-nCoV) Quarantines Source Type: news
             Basel, 28 May 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced European Medicines Agency (EMA) approval of a new, shorter two-hour OCREVUS ® (ocrelizumab) infusion time, dosed twice yearly, for relapsing or primary progressive multiple sclerosis (MS). The approval is based on a positive opinion from the EMA’s Committee for Medicinal Products for Human Use (CHMP).“The approval of a shorter, two-hour infusion time for OCREVUS in Europe, dosed twice yearly, will further improve the treatment experience for patients while als...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Chemistry | Cranberry | Disability | Laboratory Medicine | Nutrition | Pecan | Pomegranates | Raspberries | Strawberries | Study | Walnuts